Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is currently only available as a subcutaneous injection — there is no oral tablet, capsule or patch version licensed in the UK. Each KwikPen delivers one weekly dose under the skin, and that single-route delivery is how tirzepatide's dual GIP and GLP-1 mechanism is designed to work. If injections feel like a barrier, it is worth understanding what the process actually involves before ruling them out. These are prescription-only medicines; a GPhC-registered prescriber assesses suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is not a traditional syringe. It is a pre-filled, pre-dosed auto-injector with a small concealed needle, you press it against the skin and activate it; you do not handle or see the needle during use. The pen delivers one fixed dose, covers four weekly injections per pen, and then it is done. Most people are genuinely surprised by how minor the sensation is.
Treatment starts at 2.5mg, a tolerability dose that lets your body adjust gradually. The first pen's job is settling your system, not driving weight loss immediately; nausea at this stage is common but usually mild. You can read more about how the Mounjaro injection works and the full pen range on the Mounjaro injection pens page.
Injection sites are the abdomen, thigh or upper arm; you rotate between them each week to reduce localised irritation. Correct rotation matters more than most people realise, and the guidance on site selection covers the detail. One practical note: cleaning the skin with an alcohol swab before each injection is straightforward and takes seconds, alcohol swabs are available from our pharmacy if you need them.
The NHS medicines information for tirzepatide is a reliable first reference if you want to read the full list of what to expect before you start: NHS tirzepatide patient information.
Needle anxiety is real, and our prescribers hear about it most weeks. It rarely goes away by reading more about it, it responds better to doing it correctly once. The practical steps that make a difference: inject at room temperature rather than straight from the fridge, choose a fleshy site where the skin has some give, keep the pen firmly in contact with the skin for the full duration of the injection, and breathe out as you press. Small things, but they change the experience noticeably.
Bruising and soreness are the most common physical complaints, and both are almost always technique-related rather than inevitable. The step-by-step guide to injecting without bruising goes through each variable in detail. It is genuinely worth reading before your first injection rather than after.
If you are concerned about the physical process, raise it during your consultation. A prescriber can walk through the technique and, where appropriate, connect you with aftercare support. Injection anxiety is not a reason to skip clinical assessment, it is exactly the kind of thing the process exists to address.
If injections remain a hard barrier after understanding the full picture, the alternative to consider is Wegovy tablets. On 11 June 2026, the MHRA approved oral semaglutide (Wegovy) as the first GLP-1 medicine licensed in tablet form for weight management in the UK, making Britain the first country in Europe to do so.
It is a different drug from tirzepatide. Wegovy tablets contain semaglutide, a single GLP-1 receptor agonist rather than tirzepatide's dual GIP/GLP-1 action. Trial data from the OASIS 4 study reported around 13.6% average weight loss at 64 weeks, rising to roughly 17% among participants who adhered fully to treatment, the latter figure is specifically the fully-adherent group, not the population average. The tablet is taken once daily, first thing in the morning on an empty stomach, with a small amount of plain water, at least 30 minutes before food or other oral medicines. No refrigeration is needed, which does make it more straightforward for travel and day-to-day routine.
For a broader comparison of the two medicines and how each fits different circumstances, the weight-loss treatment overview sets out what is currently available through nume. Eligibility for each medicine differs; it is a clinical decision, not a product preference.
For context on how private treatment pricing works, the recent Mounjaro pricing changes page explains how Eli Lilly's list-price adjustment affects private costs, useful background if cost is part of your thinking alongside route of administration.
The right medicine and route for you depends on your health history, current medications and personal circumstances, not just the delivery format. A prescriber needs to see the whole picture before recommending tirzepatide, Wegovy tablets or anything else. That means a proper clinical assessment, not a tick-box form.
At nume, every consultation is read by a real clinician on the day it is submitted, not processed by software. If you order before 12pm on a working day and your application is approved, treatment is dispatched the same day and arrives the next working day with DPD, in plain unbranded packaging. The consultation is free, and so is the prescription if treatment goes ahead.
To learn more about what the Mounjaro treatment involves in full, or to look at what else is available, our FAQs cover the most common questions. When you are ready, you can speak to our prescribers, the consultation takes a few minutes and there is no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.